Compounds > 1,1-dimethyl-4-acetylpiperazinium
Page last updated: 2024-12-10
1,1-dimethyl-4-acetylpiperazinium
Description
You are likely asking about **1,1-dimethyl-4-acetylpiperazinium**, often abbreviated as **DMAP**. It's important to note that **DMAP is NOT 1,1-dimethyl-4-acetylpiperazinium**, but rather **4-Dimethylaminopyridine**, a common reagent in organic chemistry.
Here's why DMAP is important for research:
* **Catalysis:** DMAP is a highly effective catalyst for various reactions, particularly acylation reactions (adding an acyl group to a molecule).
* **Increased Reaction Rates:** It accelerates reactions by acting as a nucleophilic catalyst, facilitating the formation of the desired products.
* **Enhanced Selectivity:** In many cases, DMAP helps to improve the selectivity of reactions, ensuring that the desired product is formed with minimal side-products.
* **Versatility:** DMAP can be used in a wide range of reactions, including:
* Esterification
* Amide formation
* Acylation of alcohols and amines
* Transesterification
* **Widely Used:** DMAP is a staple reagent in research labs, particularly in organic synthesis, medicinal chemistry, and materials science.
**Key properties of DMAP:**
* **Strong Nucleophile:** It's a strong nucleophile due to the electron-donating effect of the dimethylamino group.
* **Excellent Leaving Group:** The pyridine ring allows for easy removal of the catalyst after the reaction is complete.
**Importance in Research:**
* **Drug Discovery:** DMAP plays a key role in the synthesis of many pharmaceuticals and drug candidates.
* **Materials Science:** It's used in the preparation of polymers, resins, and other advanced materials.
* **Organic Chemistry Research:** DMAP is a fundamental tool for developing new reactions and improving existing ones.
**Overall:** DMAP is a powerful and versatile reagent that has significantly impacted organic synthesis and various research fields. Its ability to accelerate and improve reactions makes it an indispensable tool for scientists worldwide.
1,1-dimethyl-4-acetylpiperazinium: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 4392675 |
| CHEMBL ID | 356911 |
| CHEBI ID | 94162 |
| SCHEMBL ID | 14902545 |
| MeSH ID | M0214883 |
Synonyms (19)
| Synonym |
|---|
| hpip |
| tocris-0352 |
| NCGC00024550-01 |
| 1,1-dimethyl-4-acetylpiperazinium iodide |
| NCGC00163228-01 |
| CHEMBL356911 |
| 61167-35-9 |
| piperazinium, 4-acetyl-1,1-dimethyl- |
| 1,1-dimethyl-4-acetylpiperazinium |
| BRD-K97019106-005-01-1 |
| SCHEMBL14902545 |
| DTXSID60210062 |
| CHEBI:94162 |
| 1-(4,4-dimethyl-1-piperazin-4-iumyl)ethanone |
| Q27165911 |
| BRD-K97019106-005-02-9 |
| 4-acetyl-1,1-dimethylpiperazinium |
| 4-acetyl-1,1-dimethylpiperazin-1-ium |
| AKOS040824731 |
Drug Classes (1)
| Class | Description |
|---|
| N-methylpiperazine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (5)
Potency Measurements
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID71812 | Potency (reciprocal of the equipotent molar ratio compared to carbamylcholine), estimated by contracture of the frog rectus abdominis muscle | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
| Synthesis, pharmacology, and molecular modeling studies of semirigid, nicotinic agonists. |
| AID71820 | Potency with reference to carbamylcholine at the frog neuromuscular junction, expressed as reciprocal of equipotent molar ratio | 1989 | Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
| Carbamyl analogues of potent nicotinic agonists: pharmacology and computer-assisted molecular modeling study. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.39 (24.57) | | Research Supply Index | 2.77 (2.92) | | Research Growth Index | 5.17 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |